USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PAXVAX, INC.
Address:
3985A SORRENTO VALLEY BLVD
SAN DIEGO, CA 92121
Phone:
N/A
URL:
EIN:
113780505
DUNS:
806518598
Number of Employees:
188
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,147,286.00 3
SBIR Phase II $2,971,235.00 1

Award List:

Ad4 vectored HIV-Env vaccines with improved immunogenicity

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Development of a vaccine to prevent, or reduce the rate of, HIV infections remains a high priority despite recent setbacks in the field. The lessons from failed and successful experimental programs indicate the need to apply new approaches to HIV vaccine design… More

Oral, replicating Ad4-HIV vaccine development and evaluation in NHP challenge model

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$2,971,235.00
Agency:
HHS
Principal Investigator:
Marc J. Gurwith – 858-450-9595
Abstract:
DESCRIPTION (provided by applicant): Development of a vaccine to prevent, or reduce the rate of, HIV infections remains a high priority despite recent setbacks in the field. The lessons from failed and successful experimental programs indicate the need toapply new approaches to HIV vaccine design… More

Replicating Ad4-HIV vaccine development based on improved HIV Env and GBV-C E2

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$548,822.00
Agency:
HHS
Principal Investigator:
Jeffery Alexander – 858-450-9595
Abstract:
DESCRIPTION (provided by applicant): Development of a vaccine to prevent, or reduce the rate of, HIV infections remains a high priority despite recent setbacks in the field. The lessons from failed and successful experimental programs indicate the need toapply new approaches to HIV vaccine design… More

Use of Spray-Drying as a Manufacturing Process for Oral Adenovirus Vaccine

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$298,464.00
Agency:
HHS
Principal Investigator:
Amish Patel – 858-450-9595
Abstract:
DESCRIPTION (provided by applicant): The 2009 H1N1 pandemic illustrates a critical weakness in our ability to respond to a pandemic threat. The ability to ramp up production of vaccine doses within the critical period from the discovery of the threat is hindered by two major supply constrictions: 1)… More